<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
<channel>
<title>Alligator Bioscience Ab — News on 6ix</title>
<link>https://6ix.com/company/alligator-bioscience-ab</link>
<description>Latest news and press releases for Alligator Bioscience Ab on 6ix.</description>
<language>en-us</language>
<lastBuildDate>Thu, 23 Apr 2026 08:20:00 GMT</lastBuildDate>
<generator>6ix RSS</generator>
<atom:link href="https://6ix.com/rss/company/alligator-bioscience-ab" rel="self" type="application/rss+xml" />
<image>
<url>https://6ix-events-pro.s3.amazonaws.com/6ixvideo/logos/org-logo69d562fabeedb30cb6f7fdcc.webp</url>
<title>Alligator Bioscience Ab</title>
<link>https://6ix.com/company/alligator-bioscience-ab</link>
</image>
<item>
<title>Alligator Bioscience Comments on Henlius Presentation of HLX49 Preclinical Data at AACR 2026</title>
<link>https://6ix.com/company/alligator-bioscience-ab/news/alligator-bioscience-comments-on-henlius-presentation-of-hlx49-preclinical-data-at-aacr-2026</link>
<guid isPermaLink="true">https://6ix.com/company/alligator-bioscience-ab/news/alligator-bioscience-comments-on-henlius-presentation-of-hlx49-preclinical-data-at-aacr-2026</guid>
<pubDate>Thu, 23 Apr 2026 08:20:00 GMT</pubDate>
<description>LUND, SE / ACCESS Newswire / April 23, 2026 / Alligator Bioscience (Nasdaq Stockholm:ATORX) today announced that Shanghai Henlius Biotech, Inc. has presented preclinical data for HLX49, a HER2 biparatopic antibody-drug conjugate (ADC), at the American ...</description>
</item>
<item>
<title>New Data from Investigator‑Initiated Study Evaluating Alligator Bioscience’s Mitazalimab to Be Presented at AACR Annual Meeting 2026</title>
<link>https://6ix.com/company/alligator-bioscience-ab/news/new-data-from-investigatorinitiated-study-evaluating-alligator-biosciences-mitazalimab-to-be-presented-at-aacr-annual-meeting-2026</link>
<guid isPermaLink="true">https://6ix.com/company/alligator-bioscience-ab/news/new-data-from-investigatorinitiated-study-evaluating-alligator-biosciences-mitazalimab-to-be-presented-at-aacr-annual-meeting-2026</guid>
<pubDate>Mon, 20 Apr 2026 07:05:00 GMT</pubDate>
<description>LUND, SE / ACCESS Newswire / April 20, 2026 / Alligator Bioscience (STO:ATORX), a clinical-stage biotechnology company developing tumor-directed immuno-oncology antibody drugs, today announced that new data from a Phase 1 investigator‑initiated trial ...</description>
</item>
<item>
<title>Alligator Bioscience Provides an Update on Mitazalimab</title>
<link>https://6ix.com/company/alligator-bioscience-ab/news/alligator-bioscience-provides-an-update-on-mitazalimab</link>
<guid isPermaLink="true">https://6ix.com/company/alligator-bioscience-ab/news/alligator-bioscience-provides-an-update-on-mitazalimab</guid>
<pubDate>Fri, 10 Apr 2026 12:30:00 GMT</pubDate>
<description>LUND, SE / ACCESS Newswire / April 10, 2026 / Alligator Bioscience (STO:ATORX)(Nasdaq Stockholm:ATORX), a clinical-stage biotechnology company developing tumor-directed immuno-oncology antibody drugs, today provided a brief update regarding mitazalimab. ...</description>
</item>
<item>
<title>Notice of Annual General Meeting in Alligator Bioscience AB</title>
<link>https://6ix.com/company/alligator-bioscience-ab/news/notice-of-annual-general-meeting-in-alligator-bioscience-ab</link>
<guid isPermaLink="true">https://6ix.com/company/alligator-bioscience-ab/news/notice-of-annual-general-meeting-in-alligator-bioscience-ab</guid>
<pubDate>Mon, 30 Mar 2026 07:15:00 GMT</pubDate>
<description>The English text is an unofficial translation. In case of any discrepancies between the Swedish text and the English translation, the Swedish text shall prevail. LUND, SE / ACCESS Newswire / March 30, 2026 /The shareholders of Alligator Bioscience ...</description>
</item>
<item>
<title>The Nomination Committee's Proposals Regarding the Board of Directors for the Annual General Meeting in Alligator Bioscience AB (publ)</title>
<link>https://6ix.com/company/alligator-bioscience-ab/news/the-nomination-committees-proposals-regarding-the-board-of-directors-for-the-annual-general-meeting-in-alligator-bioscience-ab-publ</link>
<guid isPermaLink="true">https://6ix.com/company/alligator-bioscience-ab/news/the-nomination-committees-proposals-regarding-the-board-of-directors-for-the-annual-general-meeting-in-alligator-bioscience-ab-publ</guid>
<pubDate>Fri, 27 Mar 2026 10:45:00 GMT</pubDate>
<description>LUND, SE / ACCESS Newswire / March 27, 2026 / Alligator Bioscience (STO:ATORX) - The Nomination Committee of Alligator Bioscience AB (publ) ("Alligator Bioscience") proposes re-election of Hans-Peter Ostler and Denise Goode as ordinary Board members ...</description>
</item>
<item>
<title>Alligator Bioscience Publishes Annual Report for 2025</title>
<link>https://6ix.com/company/alligator-bioscience-ab/news/alligator-bioscience-publishes-annual-report-for-2025</link>
<guid isPermaLink="true">https://6ix.com/company/alligator-bioscience-ab/news/alligator-bioscience-publishes-annual-report-for-2025</guid>
<pubDate>Thu, 26 Mar 2026 14:15:00 GMT</pubDate>
<description>LUND, SWEDEN / ACCESS Newswire / March 26, 2026 /Alligator Bioscience (Nasdaq Stockholm:ATORX) today announced that the Annual Report for 2025, as well as the company's Remuneration Report, has been published. Because of environmental and cost reasons, ...</description>
</item>
<item>
<title>Alligator Bioscience Strengthens Intellectual Property Protection for Bispecific Antibody Platform</title>
<link>https://6ix.com/company/alligator-bioscience-ab/news/alligator-bioscience-strengthens-intellectual-property-protection-for-bispecific-antibody-platform</link>
<guid isPermaLink="true">https://6ix.com/company/alligator-bioscience-ab/news/alligator-bioscience-strengthens-intellectual-property-protection-for-bispecific-antibody-platform</guid>
<pubDate>Tue, 10 Mar 2026 12:45:00 GMT</pubDate>
<description>LUND, SWEDEN / ACCESS Newswire / March 10, 2026 / Alligator Bioscience (STO:ATORX), a clinical-stage biotechnology company developing tumor-directed immuno-oncology antibody drugs, today announced that the United States Patent and Trademark Office ...</description>
</item>
<item>
<title>Alligator Bioscience Comments on Henlius Dosing First Patient in Phase 2/3 Breast Cancer Study of HLX22</title>
<link>https://6ix.com/company/alligator-bioscience-ab/news/alligator-bioscience-comments-on-henlius-dosing-first-patient-in-phase-23-breast-cancer-study-of-hlx22</link>
<guid isPermaLink="true">https://6ix.com/company/alligator-bioscience-ab/news/alligator-bioscience-comments-on-henlius-dosing-first-patient-in-phase-23-breast-cancer-study-of-hlx22</guid>
<pubDate>Mon, 02 Mar 2026 08:05:00 GMT</pubDate>
<description>LUND, SE / ACCESS Newswire / March 2, 2026 / Alligator Bioscience (Nasdaq Stockholm:ATORX) today comments on the announcement by Shanghai Henlius Biotech, Inc. that the first patient has been dosed in a Phase 2/3 clinical trial of HLX22 in combination ...</description>
</item>
<item>
<title>Exercise Price Determined for the Exercise of Warrants Series TO 14 in Alligator Bioscience AB</title>
<link>https://6ix.com/company/alligator-bioscience-ab/news/exercise-price-determined-for-the-exercise-of-warrants-series-to-14-in-alligator-bioscience-ab</link>
<guid isPermaLink="true">https://6ix.com/company/alligator-bioscience-ab/news/exercise-price-determined-for-the-exercise-of-warrants-series-to-14-in-alligator-bioscience-ab</guid>
<pubDate>Fri, 27 Feb 2026 17:45:00 GMT</pubDate>
<description>NOT FOR RELEASE, DISTRIBUTION OR PUBLICATION, DIRECTLY OR INDIRECTLY, IN OR INTO, THE UNITED STATES OF AMERICA, AUSTRALIA, BELARUS, CANADA, HONG KONG, JAPAN, NEW ZEALAND, RUSSIA, SINGAPORE, SOUTH AFRICA, SOUTH KOREA OR ANY OTHER JURISDICTION IN WHICH ...</description>
</item>
<item>
<title>Alligator Bioscience AB Reports Full Year Financial Results for 2025 and for Q4 2025 and Provides a Business Update</title>
<link>https://6ix.com/company/alligator-bioscience-ab/news/alligator-bioscience-ab-reports-full-year-financial-results-for-2025-and-for-q4-2025-and-provides-a-business-update</link>
<guid isPermaLink="true">https://6ix.com/company/alligator-bioscience-ab/news/alligator-bioscience-ab-reports-full-year-financial-results-for-2025-and-for-q4-2025-and-provides-a-business-update</guid>
<pubDate>Thu, 12 Feb 2026 07:15:00 GMT</pubDate>
<description>Rights issue completed: Approximately SEK 91 million (gross) raised in December, strengthening financial position with additional warrant upside in 2026. Mitazalimab validation: OPTIMIZE-1 biomarker results published in Cell Reports Medicine and REACtiVe-2 ...</description>
</item>
<item>
<title>Invitation to Alligator Bioscience's Earnings Call on 12 February 2026</title>
<link>https://6ix.com/company/alligator-bioscience-ab/news/invitation-to-alligator-biosciences-earnings-call-on-12-february-2026</link>
<guid isPermaLink="true">https://6ix.com/company/alligator-bioscience-ab/news/invitation-to-alligator-biosciences-earnings-call-on-12-february-2026</guid>
<pubDate>Thu, 05 Feb 2026 08:15:00 GMT</pubDate>
<description>LUND, SE / ACCESS Newswire / February 5, 2026 / Alligator Bioscience (Nasdaq Stockholm:ATORX)(STO:ATORX), a clinical-stage biotechnology company developing tumor-directed immuno-oncology antibody drugs, will publish its year-end report for 2025 on ...</description>
</item>
<item>
<title>Change in Number of Shares and Votes in Alligator Bioscience AB</title>
<link>https://6ix.com/company/alligator-bioscience-ab/news/change-in-number-of-shares-and-votes-in-alligator-bioscience-ab</link>
<guid isPermaLink="true">https://6ix.com/company/alligator-bioscience-ab/news/change-in-number-of-shares-and-votes-in-alligator-bioscience-ab</guid>
<pubDate>Fri, 30 Jan 2026 14:15:00 GMT</pubDate>
<description>LUND, SWEDEN / ACCESS Newswire / January 30, 2026 / Alligator Bioscience (STO:ATORX) - During January 2026, the number of shares and votes in Alligator Bioscience AB ("Alligator Bioscience") has increased as a result of the rights issue of units which ...</description>
</item>
<item>
<title>Alligator Bioscience to Present New OPTIMIZE-1 Data on Mitazalimab at ASCO Gastrointestinal Cancers Symposium 2026</title>
<link>https://6ix.com/company/alligator-bioscience-ab/news/alligator-bioscience-to-present-new-optimize-1-data-on-mitazalimab-at-asco-gastrointestinal-cancers-symposium-2026</link>
<guid isPermaLink="true">https://6ix.com/company/alligator-bioscience-ab/news/alligator-bioscience-to-present-new-optimize-1-data-on-mitazalimab-at-asco-gastrointestinal-cancers-symposium-2026</guid>
<pubDate>Fri, 09 Jan 2026 08:00:00 GMT</pubDate>
<description>LUND, SE / ACCESS Newswire / January 9, 2026 / Alligator Bioscience (Nasdaq Stockholm:ATORX), a clinical-stage biotechnology company developing tumor-directed immuno-oncology antibody drugs, today announced that new data from its Phase 1b/2 OPTIMIZE-1 ...</description>
</item>
<item>
<title>Alligator Bioscience Announces Preliminary Outcome in Rights Issue</title>
<link>https://6ix.com/company/alligator-bioscience-ab/news/alligator-bioscience-announces-preliminary-outcome-in-rights-issue</link>
<guid isPermaLink="true">https://6ix.com/company/alligator-bioscience-ab/news/alligator-bioscience-announces-preliminary-outcome-in-rights-issue</guid>
<pubDate>Fri, 19 Dec 2025 11:45:00 GMT</pubDate>
<description>NOT FOR RELEASE, DISTRIBUTION OR PUBLICATION, DIRECTLY OR INDIRECTLY, IN OR INTO, THE UNITED STATES OF AMERICA, AUSTRALIA, BELARUS, CANADA, HONG KONG, JAPAN, NEW ZEALAND, RUSSIA, SINGAPORE, SOUTH AFRICA, SOUTH KOREA OR ANY OTHER JURISDICTION IN WHICH ...</description>
</item>
<item>
<title>Alligator Bioscience Comments on Henlius Receiving Regulatory Approval in China to Initiate Phase 2/3 Trials of HLX22 in HER2-Positive Breast Cancer</title>
<link>https://6ix.com/company/alligator-bioscience-ab/news/alligator-bioscience-comments-on-henlius-receiving-regulatory-approval-in-china-to-initiate-phase-23-trials-of-hlx22-in-her2-positive-breast-cancer</link>
<guid isPermaLink="true">https://6ix.com/company/alligator-bioscience-ab/news/alligator-bioscience-comments-on-henlius-receiving-regulatory-approval-in-china-to-initiate-phase-23-trials-of-hlx22-in-her2-positive-breast-cancer</guid>
<pubDate>Tue, 09 Dec 2025 11:15:00 GMT</pubDate>
<description>LUND, SE / ACCESS Newswire / December 9, 2025 / Alligator Bioscience (Nasdaq Stockholm:ATORX)(STO:ATORX) today comments on the announcement by Shanghai Henlius Biotech, Inc. that applications for Phase 2/3 clinical trials of HLX22 (recombinant humanised ...</description>
</item>
<item>
<title>Alligator Publishes Supplement Prospectus</title>
<link>https://6ix.com/company/alligator-bioscience-ab/news/alligator-publishes-supplement-prospectus</link>
<guid isPermaLink="true">https://6ix.com/company/alligator-bioscience-ab/news/alligator-publishes-supplement-prospectus</guid>
<pubDate>Wed, 03 Dec 2025 17:15:00 GMT</pubDate>
<description>NOT FOR RELEASE, DISTRIBUTION OR PUBLICATION, DIRECTLY OR INDIRECTLY, IN OR INTO, THE UNITED STATES OF AMERICA, AUSTRALIA, BELARUS, CANADA, HONG KONG, JAPAN, NEW ZEALAND, RUSSIA, SINGAPORE, SOUTH AFRICA, SOUTH KOREA OR ANY OTHER JURISDICTION IN WHICH ...</description>
</item>
<item>
<title>Alligator Bioscience Publishes Financial Calendar for 2026</title>
<link>https://6ix.com/company/alligator-bioscience-ab/news/alligator-bioscience-publishes-financial-calendar-for-2026</link>
<guid isPermaLink="true">https://6ix.com/company/alligator-bioscience-ab/news/alligator-bioscience-publishes-financial-calendar-for-2026</guid>
<pubDate>Wed, 03 Dec 2025 08:15:00 GMT</pubDate>
<description>LUND, SE / ACCESS Newswire / December 3, 2025 / Alligator Bioscience (Nasdaq Stockholm:ATORX)(STO:ATORX), hereby publishes its financial calendar for 2026: Deadline for Alligator Bioscience's shareholders to submit resolutions to be considered by ...</description>
</item>
<item>
<title>Alligator Bioscience Enters into Additional Subscription Undertakings and Top Guarantee Commitments for the Upcoming Rights Issue</title>
<link>https://6ix.com/company/alligator-bioscience-ab/news/alligator-bioscience-enters-into-additional-subscription-undertakings-and-top-guarantee-commitments-for-the-upcoming-rights-issue</link>
<guid isPermaLink="true">https://6ix.com/company/alligator-bioscience-ab/news/alligator-bioscience-enters-into-additional-subscription-undertakings-and-top-guarantee-commitments-for-the-upcoming-rights-issue</guid>
<pubDate>Mon, 01 Dec 2025 18:00:00 GMT</pubDate>
<description>NOT FOR RELEASE, DISTRIBUTION OR PUBLICATION, DIRECTLY OR INDIRECTLY, IN OR INTO, THE UNITED STATES OF AMERICA, AUSTRALIA, BELARUS, CANADA, HONG KONG, JAPAN, NEW ZEALAND, RUSSIA, SINGAPORE, SOUTH AFRICA, SOUTH KOREA OR ANY OTHER JURISDICTION IN WHICH ...</description>
</item>
<item>
<title>Alligator Bioscience Announces Publication of REACtiVe-2 Phase 1 trial data in Nature Communications</title>
<link>https://6ix.com/company/alligator-bioscience-ab/news/alligator-bioscience-announces-publication-of-reactive-2-phase-1-trial-data-in-nature-communications</link>
<guid isPermaLink="true">https://6ix.com/company/alligator-bioscience-ab/news/alligator-bioscience-announces-publication-of-reactive-2-phase-1-trial-data-in-nature-communications</guid>
<pubDate>Mon, 01 Dec 2025 08:10:00 GMT</pubDate>
<description>LUND, SE / ACCESS Newswire / December 1, 2025 / Alligator Bioscience (Nasdaq Stockholm:ATORX)(STO:ATORX) today announced the publication of a peer-reviewed article in Nature communications, reporting data from the REACtiVe-2 clinical trial. REACtiVe-2 ...</description>
</item>
<item>
<title>Bulletin from The Extraordinary General Meeting in Alligator Bioscience AB</title>
<link>https://6ix.com/company/alligator-bioscience-ab/news/bulletin-from-the-extraordinary-general-meeting-in-alligator-bioscience-ab</link>
<guid isPermaLink="true">https://6ix.com/company/alligator-bioscience-ab/news/bulletin-from-the-extraordinary-general-meeting-in-alligator-bioscience-ab</guid>
<pubDate>Tue, 25 Nov 2025 11:00:00 GMT</pubDate>
<description>LUND, SE / ACCESS Newswire / November 25, 2025 / Alligator Bioscience (STO:ATORX) - Today, on 25 November 2025, an extraordinary general meeting was held in Alligator Bioscience AB. A summary of the adopted resolutions follows below. Resolution on ...</description>
</item>
</channel>
</rss>